

Alan J Thompson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4470751/alan-j-thompson-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291
papers

42,977
citations

83
h-index

205
g-index

320
ext. papers

49,296
ext. citations

7.9
avg, IF

6.98
L-index

#	Paper	IF	Citations
291	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
290	Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 50, 121-7	9.4	5368
289	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
288	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018 , 17, 162-173	24.1	2419
287	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
286	Multiple sclerosis. <i>Lancet</i> , The, 2018 , 391, 1622-1636	40	698
285	A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. <i>New England Journal of Medicine</i> , 2002 , 346, 158-64	59.2	694
284	Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. <i>Neurology</i> , 2014 , 83, 1022-4	6.5	674
283	The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. <i>Brain</i> , 2001 , 124, 962-73	11.2	669
282	Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. <i>Brain</i> , 2008 , 131, 808-17	11.2	659
281	Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. <i>Lancet</i> , The, 2003 , 362, 1517-26	40	583
280	Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. <i>Lancet Neurology</i> , The, 2012 , 11, 150-6	24.1	460
279	Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. <i>Cerebral Cortex</i> , 2005 , 15, 31-9	5.1	459
278	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology</i> , The, 2005 , 4, 281-8	24.1	436
277	Major differences in the dynamics of primary and secondary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 53-62	9.4	436
276	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. <i>Brain</i> , 2002 , 125, 1676-95	11.2	422
275	Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. <i>Annals of Neurology</i> , 2005 , 58, 383-91	9.4	420

274	Gray matter atrophy is related to long-term disability in multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 64, 247-54	9.4	345
273	Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. <i>Lancet Neurology</i> , <i>The</i> , 2007 , 6, 1094-105	24.1	343
272	Motor system activation after subcortical stroke depends on corticospinal system integrity. <i>Brain</i> , 2006 , 129, 809-19	11.2	317
271	New insights into the burden and costs of multiple sclerosis in Europe. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1123-1136	5	309
270	Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. <i>Lancet Neurology</i> , <i>The</i> , 2008 , 7, 715-27	24.1	300
269	Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. <i>Annals of Neurology</i> , 1997 , 42, 379-82	9.4	297
268	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. <i>Brain</i> , 2003 , 126, 2191-202	11.2	289
267	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
266	Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. <i>Brain</i> , 2004 , 127, 1101-7	11.2	277
265	MRI in multiple sclerosis: current status and future prospects. <i>Lancet Neurology</i> , <i>The</i> , 2008 , 7, 615-25	24.1	262
264	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , <i>The</i> , 2007 , 6, 677-86	24.1	246
263	The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. <i>Cerebral Cortex</i> , 2006 , 16, 811-8	5.1	236
262	Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Annals of Neurology</i> , 2002 , 52, 47-53	9.4	212
261	Exercise in patients with multiple sclerosis. <i>Lancet Neurology</i> , <i>The</i> , 2017 , 16, 848-856	24.1	210
260	Kurtzke scales revisited: the application of psychometric methods to clinical intuition. <i>Brain</i> , 2000 , 123 (Pt 5), 1027-40	11.2	199
259	Disability, atrophy and cortical reorganization following spinal cord injury. <i>Brain</i> , 2011 , 134, 1610-22	11.2	196
258	Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1407-19	5.5	195
257	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018 , 83, 210-222	9.4	185

256	Spinal-cord MRI in multiple sclerosis. <i>Lancet Neurology, The</i> , 2003 , 2, 555-62	24.1	181
255	MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study. <i>Lancet Neurology, The</i> , 2013 , 12, 873-881	24.1	178
254	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet, The</i> , 2017 , 389, 1357-1366	40	174
253	From diffusion tractography to quantitative white matter tract measures: a reproducibility study. <i>NeuroImage</i> , 2003 , 18, 348-59	7.9	174
252	Functional anatomy of interhemispheric cortical connections in the human brain. <i>Journal of Anatomy</i> , 2006 , 209, 311-20	2.9	169
251	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013 , 260, 1452-68	5.5	161
250	Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. <i>Brain</i> , 2006 , 129, 1859-71	11.2	161
249	Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. <i>Brain</i> , 2004 , 127, 1361-9	11.2	159
248	Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. <i>NeuroImage</i> , 2006 , 31, 286-93	7.9	157
247	Quality of life measurement after stroke: uses and abuses of the SF-36. <i>Stroke</i> , 2002 , 33, 1348-56	6.7	149
246	A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging--evidence of Wallerian degeneration. <i>Journal of Neurology</i> , 2003 , 250, 287-92	5.5	147
245	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , 2018 , 141, 1665-1677	11.2	146
244	Clinical outcomes assessment in multiple sclerosis. <i>Annals of Neurology</i> , 1996 , 40, 469-79	9.4	143
243	Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. <i>Human Brain Mapping</i> , 2009 , 30, 2852-61	5.8	141
242	Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. <i>Brain</i> , 2007 , 130, 2220-31	11.2	139
241	Optic nerve diffusion tensor imaging in optic neuritis. <i>NeuroImage</i> , 2006 , 30, 498-505	7.9	137
240	Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. <i>Archives of Neurology</i> , 2006 , 63, 1175-80		135
239	Characterizing function-structure relationships in the human visual system with functional MRI and diffusion tensor imaging. <i>NeuroImage</i> , 2004 , 21, 1452-63	7.9	127

238	The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. <i>Journal of Magnetic Resonance Imaging</i> , 2002 , 15, 259-67	5.6	126
237	The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke. <i>European Journal of Neuroscience</i> , 2007 , 25, 1865-73	3.5	123
236	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. <i>Brain</i> , 2005 , 128, 1454-60	11.2	123
235	Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. <i>Lancet Neurology</i> , <i>The</i> , 2010 , 9, 1182-1199	24.1	122
234	Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. <i>Journal of Neurology</i> , 2001 , 248, 131-8	5.5	120
233	The influence of time after stroke on brain activations during a motor task. <i>Annals of Neurology</i> , 2004 , 55, 829-34	9.4	114
232	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , <i>The</i> , 2005 , 4, 341-8	24.1	112
231	Identifying brain regions for integrative sensorimotor processing with ankle movements. <i>Experimental Brain Research</i> , 2005 , 166, 31-42	2.3	112
230	Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 387-91	5	110
229	Diffusion tractography based group mapping of major white-matter pathways in the human brain. <i>NeuroImage</i> , 2003 , 19, 1545-55	7.9	109
228	Optic radiation changes after optic neuritis detected by tractography-based group mapping. <i>Human Brain Mapping</i> , 2005 , 25, 308-16	5.9	108
227	Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. <i>Human Brain Mapping</i> , 2009 , 30, 615-24	5.9	107
226	A serial MRI study following optic nerve mean area in acute optic neuritis. <i>Brain</i> , 2004 , 127, 2498-505	11.2	107
225	The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. <i>Journal of Neurology</i> , 2003 , 250, 67-74	5.5	104
224	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
223	Neuroplasticity and functional recovery in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2012 , 8, 635-46	15	100
222	What sample sizes for reliability and validity studies in neurology?. <i>Journal of Neurology</i> , 2012 , 259, 2681-94	15.94	98
221	Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1534-40	5	94

220	Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. <i>Brain</i> , 2005 , 128, 2911-25	11.2	94
219	Primary progressive multiple sclerosis: a 5-year clinical and MR study. <i>Brain</i> , 2003 , 126, 2528-36	11.2	94
218	The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. <i>Trials</i> , 2011 , 12, 62	2.8	93
217	Serial magnetization transfer imaging in acute optic neuritis. <i>Brain</i> , 2004 , 127, 692-700	11.2	93
216	Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. <i>NeuroImage</i> , 2007 , 37, 253-61	7.9	92
215	Localization of grey matter atrophy in early RRMS : A longitudinal study. <i>Journal of Neurology</i> , 2006 , 253, 1495-501	5.5	89
214	A longitudinal study of cognition in primary progressive multiple sclerosis. <i>Brain</i> , 2005 , 128, 2891-8	11.2	88
213	Adaptive cortical plasticity in higher visual areas after acute optic neuritis. <i>Annals of Neurology</i> , 2005 , 57, 622-33	9.4	87
212	Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke. <i>Experimental Neurology</i> , 2004 , 190, 425-32	5.7	85
211	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018 , 14, 75-93	15	84
210	Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. <i>Journal of Neurology</i> , 2009 , 256, 305-19	5.5	83
209	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. <i>Annals of Neurology</i> , 2008 , 63, 790-3	9.4	83
208	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. <i>Brain</i> , 2006 , 129, 1031-9	11.2	83
207	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
206	Factors influencing work retention for people with multiple sclerosis: cross-sectional studies using qualitative and quantitative methods. <i>Journal of Neurology</i> , 2005 , 252, 892-6	5.5	82
205	Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999 , 11, 45-50	2.7	80
204	Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients--a randomised controlled trial. <i>Journal of Neurology</i> , 2003 , 250, 861-6	5.5	78
203	Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 566-73	5	76

202	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019 , 18, 185-197	24.1	74
201	Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. <i>Journal of Neurology</i> , 2004 , 251, 996-1005	5.5	74
200	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. <i>NeuroImage</i> , 2004 , 22, 353-9	7.9	74
199	Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. <i>Brain</i> , 2015 , 138, 2584-95	11.2	71
198	New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Annals of Neurology</i> , 2003 , 53, 673-6	9.4	68
197	Impact on clinical and cost outcomes of a centralized approach to acute stroke care in London: a comparative effectiveness before and after model. <i>PLoS ONE</i> , 2013 , 8, e70420	3.7	66
196	MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 811-7	5	65
195	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008 , 255, 683-91	5.5	65
194	Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001 , 7, 290-7	5	65
193	Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. <i>Annals of Neurology</i> , 2010 , 67, 99-113	9.4	64
192	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. <i>Journal of Neurology</i> , 1997 , 244, 76-84	5.5	64
191	Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252, 1037-44	5.5	64
190	A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 2000 , 18, 455-9	3.3	64
189	Tracking changes following spinal cord injury: insights from neuroimaging. <i>Neuroscientist</i> , 2013 , 19, 116-28	7.8	63
188	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. <i>Journal of Neurology</i> , 2008 , 255, 1-10	5.5	63
187	Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 411-5		63
186	Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. <i>Journal of Neurology</i> , 2006 , 253, 224-30	5.5	63
185	Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 844-850	5.5	62

184	Progressive neurodegeneration following spinal cord injury: Implications for clinical trials. <i>Neurology</i> , 2018 , 90, e1257-e1266	6.5	61
183	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. <i>European Journal of Neurology</i> , 2008 , 15, 113-22	6	61
182	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2003 , 17, 389-97	5.6	61
181	Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast FLAIR and fast spin echo. <i>Journal of Neurology</i> , 1997 , 244, 119-24	5.5	59
180	Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury. <i>European Journal of Neuroscience</i> , 2011 , 34, 1839-46	3.5	58
179	Traumatic and nontraumatic spinal cord injury: pathological insights from neuroimaging. <i>Nature Reviews Neurology</i> , 2019 , 15, 718-731	15	57
178	Tracking sensory system atrophy and outcome prediction in spinal cord injury. <i>Annals of Neurology</i> , 2015 , 78, 751-61	9.4	57
177	Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 207-10	5	57
176	MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers. <i>Lancet Neurology</i> , 2019 , 18, 1123-1135	24.1	56
175	Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 833-9	5.5	56
174	Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. <i>Archives of Neurology</i> , 2008 , 65, 1454-9		56
173	A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1079-87	5	55
172	Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1193-202	5	54
171	Axonal integrity predicts cortical reorganisation following cervical injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 629-37	5.5	53
170	Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: an fMRI study. <i>Neurorehabilitation and Neural Repair</i> , 2006 , 20, 398-405	4.7	53
169	The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. <i>Journal of Neurology</i> , 2002 , 249, 193-9	5.5	53
168	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1446-1453	6.5	51
167	Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 156-65	5	51

166	Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 882-91	5.5	51
165	Two-dimensional population map of cortical connections in the human internal capsule. <i>Journal of Magnetic Resonance Imaging</i> , 2007 , 25, 48-54	5.6	50
164	Degeneration of the injured cervical cord is associated with remote changes in corticospinal tract integrity and upper limb impairment. <i>PLoS ONE</i> , 2012 , 7, e51729	3.7	48
163	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. <i>Human Brain Mapping</i> , 2009 , 30, 2412-25	5.9	47
162	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. <i>Brain</i> , 2016 , 139, 816-28	11.2	46
161	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 455-64	5	46
160	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. <i>Experimental Brain Research</i> , 2008 , 187, 25-31	2.3	46
159	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. <i>Journal of Magnetic Resonance Imaging</i> , 1996 , 6, 580-4	5.6	46
158	Reproducibility of fMRI in the clinical setting: implications for trial designs. <i>NeuroImage</i> , 2008 , 42, 603-10	7.9	45
157	Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 212-8	5	44
156	Assessing neuronal metabolism in vivo by modeling imaging measures. <i>Journal of Neuroscience</i> , 2010 , 30, 15030-3	6.6	43
155	Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?. <i>Journal of Neurology</i> , 2003 , 250, 1214-8	5.5	43
154	Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. <i>Brain</i> , 2015 , 138, 1568-82	11.2	42
153	Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 875-9	5	41
152	Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 9-15	5	41
151	Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. <i>Neurology</i> , 2016 , 87, 2463-2470	6.5	40
150	Predicting outcome in clinically isolated syndrome using machine learning. <i>NeuroImage: Clinical</i> , 2015 , 7, 281-7	5.3	40
149	Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1083-90	5	40

148	Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 607-13	5	40
147	Symptomatic treatment and management of multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 122, 513-62	3	38
146	Effect sizes can be misleading: is it time to change the way we measure change?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1044-8	5.5	38
145	Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 668-77	5	38
144	Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 483-9	5	38
143	Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10 Suppl 1, S2-7	5	38
142	Two-year follow-up study of primary and transitional progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 108-14	5	38
141	The 2013 clinical course descriptors for multiple sclerosis: A clarification. <i>Neurology</i> , 2020 , 94, 1088-1092	6.5	37
140	Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years. <i>Human Brain Mapping</i> , 2013 , 34, 1163-72	5.9	37
139	Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. <i>Annals of Neurology</i> , 2013 , 74, 301-5	9.4	37
138	Upper cervical cord area in early relapsing-remitting multiple sclerosis: cross-sectional study of factors influencing cord size. <i>Journal of Magnetic Resonance Imaging</i> , 2006 , 23, 473-6	5.6	37
137	Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: a longitudinal study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 169-77	5	37
136	A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. <i>Annals of Neurology</i> , 2020 , 87, 63-74	9.4	37
135	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1472-80	5.5	35
134	Developing the ICF Core Sets for multiple sclerosis to specify functioning. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 252-4	5	34
133	Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. <i>Lancet Neurology</i> , 2006 , 5, 565-71	24.1	34
132	Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. <i>NeuroImage</i> , 2014 , 86, 257-64	7.9	33
131	Primary progressive multiple sclerosis : current and future treatment options. <i>CNS Drugs</i> , 2005 , 19, 369-76	7	33

130	Progressive MS: from pathophysiology to drug discovery. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1376-84	5	32
129	Embodied neurology: an integrative framework for neurological disorders. <i>Brain</i> , 2016 , 139, 1855-61	11.2	32
128	Exploring rating scale responsiveness: does the total score reflect the sum of its parts?. <i>Neurology</i> , 2004 , 62, 1842-4	6.5	32
127	Patient-based outcomes of cervical dystonia: a review of rating scales. <i>Movement Disorders</i> , 2004 , 19, 1054-9	7	32
126	Emergence of thalamic magnetization transfer ratio abnormality in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 276-81	5	32
125	T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 211-6	5	32
124	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. <i>Nature Communications</i> , 2021 , 12, 2078	17.4	32
123	Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 932-941	5	31
122	Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy. <i>Scientific Reports</i> , 2016 , 6, 24636	4.9	31
121	Changes in auditory feedback connections determine the severity of speech processing deficits after stroke. <i>Journal of Neuroscience</i> , 2012 , 32, 4260-70	6.6	31
120	Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. <i>Journal of Neurology</i> , 1996 , 243, 536-42	5.5	31
119	DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 461-7	5.5	30
118	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1437-1445	6.5	30
117	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2006 , 108, 456-60	2	30
116	Muscle paresis and passive stiffness: key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis. <i>Gait and Posture</i> , 2012 , 35, 266-71	2.6	28
115	Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1773-83	5	28
114	Method for simultaneous voxel-based morphometry of the brain and cervical spinal cord area measurements using 3D-MDEFT. <i>Journal of Magnetic Resonance Imaging</i> , 2010 , 32, 1242-7	5.6	28
113	Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. <i>Journal of Neurology</i> , 2002 , 249, 18-24	5.5	28

112	Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 555-65	5	27
111	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. <i>Archives of Neurology</i> , 2004 , 61, 222-4		27
110	A much-needed focus on progression in multiple sclerosis. <i>Lancet Neurology</i> , 2015 , 14, 133-5	24.1	26
109	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1459-65	5	26
108	Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 322-8	5	26
107	White and gray matter damage in primary progressive MS: The chicken or the egg?. <i>Neurology</i> , 2016 , 86, 170-6	6.5	25
106	Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin?. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 246-9	5	25
105	Quantitative MRI of rostral spinal cord and brain regions is predictive of functional recovery in acute spinal cord injury. <i>NeuroImage: Clinical</i> , 2018 , 20, 556-563	5.3	25
104	Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity. <i>Human Brain Mapping</i> , 2010 , 31, 276-86	5.9	24
103	Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. <i>Journal of Neurology</i> , 2008 , 255, 390-7	5.5	24
102	Quantification of optic nerve head topography in optic neuritis: a pilot study. <i>British Journal of Ophthalmology</i> , 2006 , 90, 1128-31	5.5	24
101	Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 398-401	5	24
100	Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. <i>Current Opinion in Neurology</i> , 2005 , 18, 267-71	7.1	24
99	Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. <i>Disability and Rehabilitation</i> , 1995 , 17, 443-8	2.4	24
98	Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1647-1657	5	24
97	Structural network disruption markers explain disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 219-226	5.5	24
96	Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. <i>FASEB Journal</i> , 2014 , 28, 117-30	0.9	23
95	T1-relaxation time changes over five years in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 427-33	5	23

94	White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1429-1437	5	22
93	Lesion enhancement diminishes with time in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 317-24	5	22
92	Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. <i>Journal of Neurology</i> , 2002 , 249, 171-7	5.5	22
91	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors Reply. <i>Lancet Neurology</i> , 2018 , 17, 499-500	24.1	22
90	Dorsal and ventral horn atrophy is associated with clinical outcome after spinal cord injury. <i>Neurology</i> , 2018 , 90, e1510-e1522	6.5	21
89	Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. <i>Journal of Magnetic Resonance Imaging</i> , 2003 , 18, 368-71	5.6	21
88	The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252, 1455-8	5.5	20
87	The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis [preliminary results]. <i>Multiple Sclerosis Journal</i> , 2001 , 7, 23-25	5	19
86	Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. <i>Neurology</i> , 2014 , 83, 1321-5	6.5	18
85	Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1066-72	5	18
84	Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 579-586	5	17
83	Metabolic changes in the spinal cord after brachial plexus root re-implantation. <i>Neurorehabilitation and Neural Repair</i> , 2013 , 27, 118-24	4.7	17
82	Challenge of progressive multiple sclerosis therapy. <i>Current Opinion in Neurology</i> , 2017 , 30, 237-240	7.1	16
81	New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 204-216	5	16
80	Evidence-based guidelines for using the Short Form 36 in cervical dystonia. <i>Movement Disorders</i> , 2007 , 22, 122-6	7	16
79	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1372-1380	5	16
78	Linking white matter tracts to associated cortical grey matter: a tract extension methodology. <i>NeuroImage</i> , 2012 , 59, 3094-102	7.9	15
77	The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 58	3	15

76	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
75	HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. <i>Neurology</i> , 2014 , 83, 1712-8	6.5	14
74	Rehabilitation of the cancer patient: experience in a neurological unit. <i>Neurorehabilitation and Neural Repair</i> , 2004 , 18, 76-9	4.7	14
73	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11020-11027	11.5	13
72	Adolescent and adult children of parents with Parkinson's disease: incorporating their needs in clinical guidelines. <i>Parkinson's Disease</i> , 2011 , 2011, 951874	2.6	13
71	Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. <i>Journal of Neurology</i> , 2003 , 250, 1037-43	5.5	13
70	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. <i>Neurology</i> , 2020 , 95, e2966-e2976	6.5	13
69	Age related changes in metabolite concentrations in the normal spinal cord. <i>PLoS ONE</i> , 2014 , 9, e105774	3.7	12
68	A novel approach with "skeletonised MTR" measures tract-specific microstructural changes in early primary-progressive MS. <i>Human Brain Mapping</i> , 2014 , 35, 723-33	5.9	11
67	Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 178-85	5	11
66	Rehabilitation in a neuroscience centre: the role of expert assessment and selection. <i>International Journal of Therapy and Rehabilitation</i> , 1996 , 3, 303-308		11
65	Asymmetric hemispheric representation of periauricular heart rate modulation is individually lateralised. <i>Epileptic Disorders</i> , 2011 , 13, 172-6	1.9	10
64	Refinement and validation of the Parental Illness Impact Scale. <i>Parkinsonism and Related Disorders</i> , 2010 , 16, 181-5	3.6	10
63	The patient's experience of being a human subject. <i>Journal of the Royal Society of Medicine</i> , 2008 , 101, 416-22	2.3	10
62	Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. <i>Human Brain Mapping</i> , 2014 , 35, 993-1003	5.9	9
61	Improving function: a new treatment era for multiple sclerosis?. <i>Lancet, The</i> , 2009 , 373, 697-8	4.0	9
60	Progress in neurorehabilitation in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2002 , 15, 267-70	7.1	9
59	Towards treating progressive multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020 , 16, 589-590	15	9

58	Clinical relevance of cortical network dynamics in early primary progressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 442-456	5	9
57	Unified understanding of MS course is required for drug development. <i>Nature Reviews Neurology</i> , 2018 , 14, 191-192	15	8
56	Scanning laser polarimetry quantification of retinal nerve fiber layer thinning following optic neuritis. <i>Journal of Neuro-Ophthalmology</i> , 2010 , 30, 235-42	2.6	8
55	Socio-demographic variables are limited predictors of health status in multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1088-93	5.5	8
54	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 28-38	5	8
53	The size of the treatment effect: do patients and proxies agree?. <i>BMC Neurology</i> , 2009 , 9, 12	3.1	7
52	A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 905-13	5.5	7
51	Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010 , 220, 99-103	3.5	7
50	Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. <i>BMC Neurology</i> , 2008 , 8, 2	3.1	7
49	The impact of inpatient neurorehabilitation on psychological well-being on discharge and at 3 month follow-up. <i>Journal of Neurology</i> , 2005 , 252, 814-9	5.5	7
48	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
47	Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1999 , 354, 1687-95	5.8	6
46	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. <i>Brain</i> , 2021 , 144, 1384-1395	11.2	6
45	Atopic myelitis in a European woman residing in Japan. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1022-4	5.5	5
44	Integrated care pathways: evaluating inpatient rehabilitation in stroke. <i>International Journal of Therapy and Rehabilitation</i> , 1997 , 4, 97-102		5
43	Patient dissatisfaction: insights into the rehabilitation process. <i>Journal of Neurology</i> , 2004 , 251, 1094-7	5.5	5
42	Author response: Progressive neurodegeneration following spinal cord injury: Implications for clinical trials. <i>Neurology</i> , 2018 , 91, 985	6.5	5
41	Advancing trial design in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1571-1572	5	4

40	Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 309-314	5	4
39	A predictive model for corticosteroid response in individual patients with MS relapses. <i>PLoS ONE</i> , 2015 , 10, e0120829	3.7	4
38	A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS). <i>Health and Quality of Life Outcomes</i> , 2011 , 9, 80	3	4
37	Longitudinal changes of spinal cord grey and white matter following spinal cord injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1222-1230	5.5	4
36	Multiple Sclerosis International Federation: stimulating international cooperation in research. <i>Neurology</i> , 2013 , 81, 1793-5	6.5	3
35	Multiple Sclerosis and Demyelinating Diseases 411-447		3
34	Management of spasticity in hereditary spastic paraplegia. <i>Physiotherapy Research International</i> , 1999 , 4, 68-76	1.8	3
33	Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2001 , 7, 75-82	5	3
32	Multiple sclerosis: the upward trajectory continues. <i>Lancet Neurology</i> , 2017 , 16, 10-12	24.1	2
31	Disrupted principal network organisation in multiple sclerosis relates to disability. <i>Scientific Reports</i> , 2020 , 10, 3620	4.9	2
30	A little bit of toxin does you good?. <i>Physiotherapy Research International</i> , 1996 , 1, 141-7	1.8	2
29	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. <i>NeuroImage: Clinical</i> , 2021 , 33, 102904	5.3	2
28	Multiple Sclerosis and Demyelinating Diseases 2016 , 475-511		1
27	The physiopathology of multiple sclerosis 8-21		1
26	Chapter 1 The Diagnosis of Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003 , 27, 1-11		1
25	Evaluating the role of botulinum toxin type A in adults with focal spasticity. <i>European Journal of Neurology</i> , 1999 , 6, s75-s75	6	1
24	Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211059766	5	1
23	Conduction studies in multiple sclerosis 1-7		1

22	Clinical trials to test rehabilitation157-164		1
21	Application of mechanistic methods to clinical trials in multiple sclerosis: the simvastatin case		1
20	Progression of regional grey matter atrophy in multiple sclerosis		1
19	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients.. <i>NeuroImage: Clinical</i> , 2022 , 34, 102985	5.3	0
18	SPINAL CORD GLUTAMATE-GLUTAMINE IS ELEVATED IN MS RELAPSE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e4.30-e4	5.5	
17	Treatment for patients with primary progressive multiple sclerosis604-613		
16	Value and limits of rehabilitation in multiple sclerosis140-151		
15	Electrophysiological assessment in multiple sclerosis112-119		
14	Spasticity in multiple sclerosis165-175		
13	Chapter 20 Rehabilitation in Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003 , 27, 317-328		
12	Chapter 22 Treatment of Progressive Multiple Sclerosis. <i>Blue Books of Practical Neurology</i> , 2003 , 27, 341-359		
11	The diagnosis and management of multiple sclerosis 2002 , 1620-1632		
10	Neurorehabilitation in Multiple Sclerosis. <i>Topics in Spinal Cord Injury Rehabilitation</i> , 2008 , 14, 63-75	1.5	
9	Brenda Banwell 2021 , 609-611		
8	Magnetic resonance imaging to study white matter damage in multiple sclerosis79-85		
7	Magnetic resonance imaging to assess gray matter damage in multiple sclerosis86-92		
6	Application of functional magnetic resonance imaging in multiple sclerosis93-102		
5	Functional magnetic resonance imaging in focal CNS damage103-111		

- 4 Functional magnetic resonance imaging monitoring of therapeutic interventions in multiple sclerosis120-126
- 3 How to measure the effects of rehabilitation127-139
- 2 Prognosis in neurorehabilitation152-156
- 1 Back home230-239